Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 7/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAN2A1 | Q16706 | 1/20 | 0.31 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4439291 | 1.00 | REN (0.38) | RENKCNH2GBA1CYP3A4MAN2A1 | |
| SCHEMBL4583013 | 0.82 | SLC6A1 (0.32) | — | |
| SCHEMBL1039869 | 0.82 | GBA1 (0.36) | GBA1 | |
| SCHEMBL1038997 | 0.82 | GBA1 (0.36) | GBA1 | |
| SCHEMBL1039871 | 0.82 | GBA1 (0.36) | GBA1 | |
| SCHEMBL1038998 | 0.82 | GBA1 (0.36) | GBA1 | |
| SCHEMBL3874317 | 0.80 | RORC (0.35) | — | |
| SCHEMBL3874324 | 0.80 | RORC (0.35) | — | |
| SCHEMBL3873570 | 0.73 | REN (0.32) | RENGBA1 | |
| SCHEMBL3873577 | 0.73 | REN (0.32) | RENGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625893-B2 | Substituted 4-phenyl piperidines for use as renin inhibitors | SPEEDEL EXPERIMENTA AG (CH) | 2009-12-01 | — | — | US | disclosed |
| US-20090088426-A1 | Substituted 4-Phenyl Piperidines for Use as Renin Inhibitors | SPEEDEL EXPERIMENTA AG | 2009-04-02 | — | — | US | disclosed |
| EP-1934207-B1 | SUBSTITUTED 4-PHENYL PIPERIDINES FOR USE AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2009-03-11 | — | — | EP | disclosed |
| EP-1911758-A1 | Phenyl piperidine derivatives for use as renin inhibitors | Speedel Experimenta AG (CH) | 2008-04-16 | — | — | EP | disclosed |
| EP-1908762-A2 | Organic compounds | Speedel Experimenta AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| EP-1908761-A1 | Organic compounds | Speedel Experimenta AG (CH) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088426-A1 | Substituted 4-Phenyl Piperidines for Use as Renin Inhibitors | REN, AGTR1, ACE | REN 1/4885KCNH2 53/4885GBA1 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.